3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Multiple Myeloma
8
Lymphoma, Non-Hodgkin
4
Leukemia, Myeloid, Acute
3
Hematologic Neoplasms
3
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Glioblastoma
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Amyloidosis
1
Interventions
Oxaliplatin
2
Leucovorin
2
Gemcitabine
2
Fluorouracil
2
Bevacizumab
2
Azacitidine
2
temsirolimus
1
ruxolitinib
1
rucaparib
1
repotrectinib
1
fludarabine
1
ceritinib
1
cc-486
1
abiraterone
1
Uncertainty
1
Thalidomide
1
Temozolomide
1
Suspensions
1
Sorafenib
1
Quality of Life
1
Psychosocial Intervention
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Molecular Diagnostic Techniques
1
Lenalidomide
1
Irinotecan
1
Interleukin-2
1
Injections
1
Immunotherapy
1
INCB057643
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Interleukin-2
×
Plasma cell
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled